<DOC>
	<DOCNO>NCT02985866</DOCNO>
	<brief_summary>The objective study assess efficacy safety home use Control-to-Range ( CTR ) closed-loop ( CL ) system .</brief_summary>
	<brief_title>The International Diabetes Closed Loop ( iDCL ) Trial : Main Protocol</brief_title>
	<detailed_description>The protocol 6-month parallel group multi-center randomize trial design compare Control-to-Range ( CTR ) closed-loop ( CL ) sensor augment pump therapy ( SAP ) . Approximately 240 subject enter randomized trial approximately ten clinical site United States Europe , least 207 subject complete randomize trial . The goal randomize approximately 115 subject HbA1c ≥7.5 % 125 subject HbA1c &lt; 7.5 % , minimum 92 subject HbA1c &lt; 7.5 % 86 HbA1c &gt; 7.5 % .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Clinical diagnosis , base investigator assessment , type 1 diabetes least one year use insulin least 1 year 2 . Use insulin pump least 6 month 3 . Age ≥14 year old 4 . HbA1c level &lt; 10.5 % screen 5 . For female , currently know pregnant 6 . Willingness add glucoselowering agent ( Pramlintide , Metformin , GLP1 analog , SGLT2 inhibitor ) study 7 . Willingness , use closedloop system , stop closedloop take acetaminophen avoid closedloop least 4 hour afterward 8 . Willingness suspend use personal CGM duration clinical trial unblinded study CGM use 9 . Willingness establish network connectivity least weekly basis either via local Wifi network via studyprovided cellular service 10 . Currently use insulin one follow rapidacting insulin time enrollment : insulin lispro ( Humalog ) , insulin aspart ( Novolog ) , insulin glulisine ( Apidra ) 11 . Investigator confidence subject successfully operate study device capable adhere protocol 1 . More one episode diabetic ketoacidosis ( DKA ) 6 month prior enrollment 2 . More one episode severe hypoglycemia involve seizure loss consciousness 6 month prior enrollment 3 . Medical need chronic acetaminophen 4 . Use glucoselowering agent ( Pramlintide , Metformin , GLP1 analog , SGLT2 inhibitor ) 3 month prior enrollment 5 . Hemophilia bleed disorder 6 . A condition , opinion investigator designee , would put participant study risk 7 . Participation another pharmaceutical device trial time enrollment study 8 . Use closedloop system within last month prior enrollment 9 . Employed , immediate family member employ TypeZero Technologies , LLC</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Artificial Pancreas</keyword>
	<keyword>Closed Loop Control</keyword>
	<keyword>Continuous Glucose Monitor ( CGM )</keyword>
</DOC>